Chengdu Jingrunze Gene Technology

Chengdu Jingrunze Gene Technology is a Chinese biotechnology company specializing in the development of next-generation gene therapies through advanced viral vector engineering. The company utilizes a proprietary high-throughput screening platform to design and optimize Adeno-associated virus (AAV) capsids, aiming to improve tissue specificity and reduce immunogenicity compared to traditional vectors. Its primary research focus includes treatments for inherited retinal diseases and various metabolic disorders. By integrating directed evolution and rational design, Jingrunze seeks to overcome the delivery barriers currently limiting the efficacy of genetic medicines. The firm is positioned within the Chengdu medical technology ecosystem, leveraging local clinical and research expertise to advance its pipeline toward human trials.